SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-20-016154
Filing Date
2020-06-29
Accepted
2020-06-29 18:03:16
Documents
47
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q rasp-20200331.htm   iXBRL 10-Q 852034
7 EXHIBITS 10.1 ex101_1.htm EX-10.1 143859
8 EXHIBITS 31.1 ex311_2.htm EX-31.1 16524
9 EXHIBITS 32.1 ex321_3.htm EX-32.1 6092
  Complete submission text file 0001213900-20-016154.txt   4885280

Data Files

Seq Description Document Type Size
2 DEFINITION rasp-20200331_def.xml EX-101.DEF 265161
3 PRESENTATION rasp-20200331_pre.xml EX-101.PRE 411446
4 CALCULATION rasp-20200331_cal.xml EX-101.CAL 44875
5 LABEL rasp-20200331_lab.xml EX-101.LAB 822058
6 SCHEMA rasp-20200331.xsd EX-101.SCH 51388
10 EXTRACTED XBRL INSTANCE DOCUMENT rasp-20200331_htm.xml XML 531573
Mailing Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170 646-396-4087
Rasna Therapeutics Inc. (Filer) CIK: 0001582249 (see all company filings)

IRS No.: 392080103 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 333-191083 | Film No.: 20997930
SIC: 2834 Pharmaceutical Preparations